Ann Van de Velde

1.2k citations

29 papers · 373 indexed · h-index 10

Co-authors: Zwi Berneman Wilfried Schroyens Jan Michiels Marc van der Planken Viggo Van Tendeloo Alain Gadisseur Nathalie Cools Sébastien Anguille
Topics: Immunotherapy and Immune Responses (9 papers)Multiple Myeloma Research and Treatments (7 papers)CAR-T cell therapy research (6 papers)
Cited by: Hematology Virology Immunology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
Partner nations: Belgium Netherlands United Kingdom

In The Last Decade

Ann Van de Velde

26 papers receiving 363 citations

Peers

Countries citing papers authored by Ann Van de Velde

Since Specialization

Citations

This map shows the geographic impact of Ann Van de Velde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Van de Velde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Van de Velde more than expected).

Fields of papers citing papers by Ann Van de Velde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Van de Velde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Van de Velde. The network helps show where Ann Van de Velde may publish in the future.

Co-authorship network of co-authors of Ann Van de Velde

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Van de Velde. A scholar is included among the top collaborators of Ann Van de Velde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Van de Velde. Ann Van de Velde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives 2024 ·SHILAP Revista de lepidopterología ·(unknown),Stef Meers,(unknown),(unknown),Koen Theunissen,Koen Van Eygen,Nathan De Beule,(unknown),(unknown),(unknown),Jan Lemmens,Ann Van de Velde,Dominik Selleslag,Jason Bouziotis,Ann De Becker,Sébastien Anguille	0
2	Combined Results of Two Cross-Sectional Surveys on the Participation in Clinical Trials and the e-Consent Procedure in the Landscape of Haematology 2023 ·SHILAP Revista de lepidopterología ·(unknown),Stef Meers,Ann Van de Velde,Sébastien Anguille	0
3	P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Michel Delforge,Sébastien Anguille,Julien Depaus,Nathalie Meuleman,Ann Van de Velde,(unknown),Joris Diels,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	1
4	Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice 2022 ·HemaSphere ·Michel Delforge,Marie‐Christiane Vekemans,Julien Depaus,(unknown),Ann Van de Velde,Isabelle Vande Broek,(unknown),(unknown),(unknown),(unknown),Joris Diels,Francesca Ghilotti,(unknown),(unknown),William Deraedt,Sébastien Anguille	0
5	PF694 TREATMENT‐FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM 2019 ·HemaSphere ·Ann Janssens,Yves Béguin,Catherine Lambert,Dimitri Breems,Dries Deeren,André Efira,Karel Fostier,Maike Janssen,Alain Kentos,(unknown),Philippe Mineur,(unknown),(unknown),Koen Theunissen,(unknown),Ann Van de Velde,Koen Van Eygen,(unknown),Dominik Selleslag	1
6	COMPARISON OF THE POWER OF PROCALCITONIN AND C-REACTIVE PROTEIN TO DISCRIMINATE BETWEEN DIFFERENT AETIOLOGIES OF FEVER IN PROLONGED PROFOUND NEUTROPENIA: A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY. 2019 ·Mediterranean Journal of Hematology and Infectious Diseases ·Anke Verlinden,Véronique De Vroey,Herman Goossens,Ella Roelant,Ann Van de Velde,Zwi Berneman,Wilfried Schroyens,Alain Gadisseur	9
7	A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis 2018 ·Acta Neurologica Belgica ·Guy Laureys,Barbara Willekens,Ludo Vanopdenbosch,Olivier Deryck,Dominik Selleslag,Miguel D’haeseleer,Ann De Becker,Bénédicte Dubois,Daan Dierickx,Gaetano Perrotta,Virginie De Wilde,Vincent Van Pesch,Nicole Straetmans,Dominique Dive,Yves Béguin,Bart Van Wijmeersch,Koen Theunissen,Tessa Kerre,Ann Van de Velde	7
8	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells 2014 ·Transplantation ·Amaryllis H. Van Craenenbroeck,Evelien Smits,Sébastien Anguille,Ann Van de Velde,Barbara Stein,Tessa Braeckman,(unknown),Griet Nijs,Margareta Ieven,Herman Goossens,Zwi Berneman,Viggo Van Tendeloo,Gert A. Verpooten,Pierre Van Damme,Nathalie Cools	25
9	Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium 2014 ·Acta Clinica Belgica ·Dominik Selleslag,Catherine Lambert,Pierre Zachée,(unknown),Ann Van de Velde,Lucien Noens,(unknown),Marc André,E. Willems,Daan Dierickx	1
10	Prevention Of Relapse In Acute Myeloid Leukemia By Dendritic Cell Vaccination: Report on a Phase II Study With 29 Patients 2013 ·Blood ·Zwi Berneman,Ann Van de Velde,Sébastien Anguille,Yannick Willemen,Wilfried Schroyens,Alain Gadisseur,Inge Vrelust,Griet Nijs,Barbara Stein,Nathalie Cools,Ronald Malfait,Marie-Berthe Maes,Katrien Vermeulen,Viggo Van Tendeloo,Evelien Smits	7
11	Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium. 2012 ·PubMed ·Michel Delforge,A. Michiels,(unknown),Alain Kentos,Jan Van Droogenbroeck,Fritz Offner,(unknown),H Demuynck,Marie Christiane Vekemans,Nathalie Meuleman,Philippe Mineur,Christophe Ravoet,(unknown),Ann Van de Velde,P. Pierre,Ka Lung Wu,Rik Schots	4
12	WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. 2012 ·Journal of Clinical Oncology ·Zwi Berneman,Ann Van de Velde,Sébastien Anguille,Nathalie Cools,Ann Van Driessche,Griet Nijs,Barbara Stein,Inge Vrelust,Alain Gadisseur,Wilfried Schroyens,Viggo Van Tendeloo,Evelien Smits	4
13	mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients 2011 ·AIDS ·Ellen Van Gulck,Erika Vlieghe,Marc Vekemans,Viggo Van Tendeloo,Ann Van de Velde,Evelien Smits,Sébastien Anguille,Nathalie Cools,Herman Goossens,(unknown),Winni De Haes,(unknown),Éric Florence,Guido Vanham,Zwi Berneman	89
14	Multicentric plasma cell variant Castleman's disease presenting with cutaneous vasculitis and pulmonary parenchymal involvement in a patient with ankylosing spondylitis: case report and review of the literature. 2011 ·PubMed ·Michael Wolf,J.F. Van Offel,Ann Van de Velde,W. J. Stevens,Luc S. De Clerck	8
15	Efficient mRNA electroporation of peripheral blood mononuclear cells to detect memory T cell responses for immunomonitoring purposes 2010 ·Journal of Immunological Methods ·(unknown),Nathalie Cools,B. Stein,Ann Van de Velde,Herman Goossens,Zwi Berneman,Viggo Van Tendeloo	23
16	Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms’ Tumor Protein WT1: A Phase I/II Trial. 2007 ·Blood ·Zwi Berneman,Ann Van Driessche,Ann Van de Velde,Griet Nijs,Tessa Braeckman,Barbara Stein,Katrien Vermeulen,Katrien Pieters,Alain Gadisseur,Wilfried Schroyens,I. Jolanda de Vries,David A. Price,Viggo Van Tendeloo	2
17	Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease 2006 ·Clinical and Applied Thrombosis/Hemostasis ·Jan Michiels,Zwi Berneman,Alain Gadisseur,Marc van der Planken,Wilfried Schroyens,Ann Van de Velde,(unknown)	39
18	Characterization, Classification, and Treatment of von Willebrand Diseases: A Critical Appraisal of the Literature and Personal Experiences 2005 ·Seminars in Thrombosis and Hemostasis ·Jan Michiels,Alain Gadisseur,Ulrich Budde,Zwi Berneman,Marc van der Planken,Wilfried Schroyens,Ann Van de Velde,(unknown)	26
19	Bortezomib-induced Sweet's syndrome. 2005 ·PubMed ·Niels Van Regenmortel,(unknown),Hendrik De Raeve,Serge A.R.B. Rombouts,Ann Van de Velde,Jo Lambert,Wilfried Schroyens	28
20	Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications 2002 ·Seminars in Thrombosis and Hemostasis ·Jan Michiels,Ann Van de Velde,Huub H.D.M. van Vliet,Marc van der Planken,Wilfried Schroyens,Zwi Berneman	37

About Ann Van de Velde

Ann Van de Velde is a scholar working on Hematology, Oncology and Immunology, having authored 29 papers that have together received 373 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (9 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Hematology (153 citations), Virology (34 citations) and Immunology (121 citations). Ann Van de Velde has collaborated with scholars based in Belgium, Netherlands and United Kingdom. Frequent co-authors include Zwi Berneman, Wilfried Schroyens, Jan Michiels, Marc van der Planken, Viggo Van Tendeloo, Alain Gadisseur, Nathalie Cools, Sébastien Anguille, Evelien Smits and Huub H.D.M. van Vliet. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact